If you are interested in more information about a particular trial, please talk with your treating physician first, and they may contact this centre for further information if necessary.
| TUMOUR GROUP/SITE | TRIAL SUMMARY | OPENING DATE |
|---|
BREAST
| Evaluation of the Ductal Carcinoma In Situ Score for Decisions on Radiotherapy in Patients with Low/Intermediate Risk DCIS
(DUCHESS)
| Apr 2018
|
| Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer.
(BWEL MAC.20)
| Mar 2018
|
| CENTRAL NERVOUS SYSTEM (CNS) |
| |
| GASTROINTESTINAL (GI) | | |
| GENITOURINARY (GU) - Prostate | This study will examine the use of stereotactic ablative radiotherapy, in which patients are given only a few, high dose radiation treatments. Treatments are short, non-invasive, applicable to patients not able to do brachytherapy, and may be more effective than conventional external beam radiation therapy.
(ASSERT) | Apr 2016 |
GENITOURINARY (GU) - Kidney
| | |
| GENITOURINARY (GU) - Bladder |
| |
| GYNE - Ovary | IROC - The Immune Response to Ovarian Cancer
(*Deeley Research Centre) | Aug 2007 |
| HEAD AND NECK |
| |
LUNG
|
| |
| LYMPHOMA | IROL - The Immune Response to Lymphoma
(*Deeley Research Centre) | Mar 2008 |
| MELANOMA |
| |
| SARCOMA | | |
| SUPPORTIVE / PALLIATIVE CARE | | |
| SYMPTOM MANAGMENT | A Randomized Phase II/III Study Comparing Stereotactic Body Radiotherapy(SBRT) versus Conventional Palliative Radiotherapy (CRT) for Patients with Spinal Metastases
(SC24)
| Nov 2017
|
| MULTI SITE | A non-randomized phase II trial where all participants will receive experimental Stereotactic Ablative Radiotherapy (SABR) to all sites of progressing metastatic disease
(SABR-5/SABR for Oligometastases)
| Jan 2017 |
| Personal REsponse Determinants in Cancer Therapy - (PREDICT) | Jan 2006 |
